The Sarah Greene Breakthrough Research Unit, King’s College London
Researchers at the Unit are dedicated to understanding which molecules and pathways define triple negative breast cancer (TNBC) and are responsible for its aggressiveness. This will underpin the development of new treatments for this devastating disease. Since the Unit was established, Elodie and Sheeba have helped understand how TNBC works and opened up new avenues for treatment. Already the team have:
• Identified four new genes that may drive TNBC and further 164 genes that will now be investigated further. The team is currently investigating the potential for treatments that block these genes.
• Shown that 20% of women with TNBC carry a mutation in the BRCA1 gene that can be inherited, meaning close female relatives may also be at higher risk of developing breast cancer.
• Found 7 new molecular markers that predict patients at high-risk of developing secondary breast cancer.
• Created a practice-changing study called the Triple Negative Trial, which is aiming to work out which of two chemotherapy drugs work best for women with triple negative breast cancer, and are working to develop new drugs for these patients.
Update: The King’s College London Research unit underwent a very successful scientific review in February 2018, and a forthcoming report will show the incredible impact of all the fundraising the SGTF has done and continues to do. Breast Cancer Now thanks the Sarah Greene Tribute Fund for their generous support of Prof Tony Ng’s and Prof Andrew Tutt’s work, at the Breast Cancer Now Research Unit at King’s College London.